What is Transluminal Technologies?
Transluminal Technologies operates at the intersection of material science and clinical surgery, specializing in the development of innovative medical devices. The company is best known for pioneering the world's first bioabsorbable magnesium alloy closure device, a breakthrough that addresses critical needs for safety and efficiency in vascular and surgical procedures. Their flagship product portfolio, including the velox CD and velox LB systems, provides healthcare professionals with sophisticated tools designed to optimize patient recovery times and minimize long-term complications. By focusing on high-performance, absorbable materials, the firm is redefining standards for closure technologies within the global medical device market.
How much funding has Transluminal Technologies raised?
Transluminal Technologies has raised a total of $1.5M across 1 funding round:
Private Equity
$1.5M
Private Equity (2013): $1.5M, investors not publicly disclosed
Key Investors in Transluminal Technologies
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Transluminal Technologies?
With the recent influx of capital, Transluminal Technologies is well-positioned to accelerate its research and development pipeline and expand its commercial footprint. The strategic focus will likely shift toward scaling manufacturing capabilities to support broader institutional adoption of their magnesium alloy devices. Furthermore, the company is expected to leverage this financial backing to conduct additional clinical trials, thereby strengthening the evidence base for their technology and facilitating regulatory approvals in new international markets. As the firm transitions into this next phase of maturity, the emphasis will remain on enhancing patient outcomes through continuous innovation in bioabsorbable medical solutions.
See full Transluminal Technologies company page
